Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Unyong | - |
dc.contributor.author | Jin, Ming Ji | - |
dc.contributor.author | Lee, Jaeick | - |
dc.contributor.author | Han, Sang Beom | - |
dc.contributor.author | In, Moon Kyo | - |
dc.contributor.author | Yoo, Hye Hyun | - |
dc.date.accessioned | 2024-01-20T15:00:54Z | - |
dc.date.available | 2024-01-20T15:00:54Z | - |
dc.date.created | 2021-09-05 | - |
dc.date.issued | 2012-05 | - |
dc.identifier.issn | 0731-7085 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/129281 | - |
dc.description.abstract | (6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210) is a synthetic cannabinoid, with a classical cannabinoid structure similar to Delta(9)-tetrahydrocannabinol (Delta(9)-THC). In this study, the in vitro metabolism of HU-210 was investigated in human liver microsomes to characterize associated phase I metabolites. HU-210 was incubated with human liver microsomes, and the reaction mixture was analyzed using LC-MS/MS. HU-210 was metabolized in human liver microsomes, yielding about 24 metabolites. These metabolites were structurally characterized on the basis of accurate mass analyses and MS/MS fragmentation patterns. The major metabolic route for HU-210 was oxygenation. Metabolites M1-M7 were identified as mono-oxygenated metabolites; MB-M15, mono-hydroxylated metabolites; M16-M20, di-oxygenated metabolites; and M21-M24, di-hydroxylated metabolites. These results provide evidence for in vivo HU-210 metabolism, and they may be applied to the analysis of HU-210 and its relevant metabolites in biological samples. (C) 2012 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER | - |
dc.subject | JWH-018 | - |
dc.subject | SYSTEM | - |
dc.title | Tentative identification of phase I metabolites of HU-210, a classical synthetic cannabinoid, by LC-MS/MS | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jpba.2012.02.007 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, v.64-65, pp.26 - 34 | - |
dc.citation.title | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | - |
dc.citation.volume | 64-65 | - |
dc.citation.startPage | 26 | - |
dc.citation.endPage | 34 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000303074800004 | - |
dc.identifier.scopusid | 2-s2.0-84862784914 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | JWH-018 | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordAuthor | HU-210 | - |
dc.subject.keywordAuthor | Synthetic cannabinoid | - |
dc.subject.keywordAuthor | Metabolism | - |
dc.subject.keywordAuthor | LC-MS/MS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.